Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fibrobody Small Molecule Conjugate (Pulmonary Hypertension)
- Development stage
- Preclinical
- Lead developer
- Linxis Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular, Subcutaneous, Inhalation, Intranasal, Transdermal, Rectal, Topical
01
Overview
Fibrobody Small Molecule Conjugate (Pulmonary Hypertension) is an experimental therapeutic being developed by Linxis Biopharmaceuticals for the treatment of idiopathic pulmonary hypertension. It belongs to a class of targeted therapies called Fibrobody® conjugates, which utilize small, high-affinity protein scaffolds to deliver therapeutic payloads—in this case, a small molecule—directly to fibrotic tissues. The platform is designed to target activated fibroblasts, which play a central role in the vascular remodeling and fibrosis associated with pulmonary hypertension. While the specific payload and molecular target for this program have not been publicly disclosed, the Linxis platform frequently targets Platelet-Derived Growth Factor Receptor Beta (PDGFRB) to inhibit fibrotic progression.
- Brand names
- Fibrobody
- Other names
- Fibrobody Small Molecule Conjugate (IPH)
02
Targets
PDGFRB (Platelet-derived growth factor receptor beta)
Beyond the preview
Go deeper on Fibrobody Small Molecule Conjugate (Pulmonary Hypertension).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fibrobody Small Molecule Conjugate (Pulmonary Hypertension).